Elizabeth Ahern

1.4k total citations
37 papers, 583 citations indexed

About

Elizabeth Ahern is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Elizabeth Ahern has authored 37 papers receiving a total of 583 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 10 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Elizabeth Ahern's work include Cancer Immunotherapy and Biomarkers (10 papers), Immunotherapy and Immune Responses (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Elizabeth Ahern is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Immunotherapy and Immune Responses (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Elizabeth Ahern collaborates with scholars based in Australia, United States and France. Elizabeth Ahern's co-authors include Mark J. Smyth, William C. Dougall, Michele W.L. Teng, Heidi Harjunpää, Stacey Allen, Brett Hughes, Deborah S. Barkauskas, Jake S. O’Donnell, David Wyld and Kazuyoshi Takeda and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Elizabeth Ahern

35 papers receiving 580 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elizabeth Ahern Australia 12 424 176 159 119 65 37 583
Gregory Pennock United States 8 384 0.9× 153 0.9× 113 0.7× 132 1.1× 17 0.3× 22 527
Limei Yin China 11 243 0.6× 129 0.7× 143 0.9× 67 0.6× 40 0.6× 19 508
Taylor R. Cushman United States 16 492 1.2× 273 1.6× 92 0.6× 243 2.0× 72 1.1× 27 727
Laura Mansi France 12 228 0.5× 57 0.3× 85 0.5× 94 0.8× 20 0.3× 30 373
Giulia Mazzaschi Italy 11 444 1.0× 166 0.9× 130 0.8× 254 2.1× 58 0.9× 54 634
Edit Porpaczy Austria 15 218 0.5× 88 0.5× 160 1.0× 38 0.3× 176 2.7× 27 614
Fiona Miall United Kingdom 13 435 1.0× 171 1.0× 49 0.3× 41 0.3× 35 0.5× 32 758
Lucía Teijeira Spain 10 400 0.9× 211 1.2× 48 0.3× 100 0.8× 14 0.2× 18 485
Pia Herbolsheimer United States 17 664 1.6× 111 0.6× 200 1.3× 139 1.2× 110 1.7× 32 777
Henriette Lindberg Denmark 14 167 0.4× 83 0.5× 76 0.5× 268 2.3× 122 1.9× 40 599

Countries citing papers authored by Elizabeth Ahern

Since Specialization
Citations

This map shows the geographic impact of Elizabeth Ahern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Ahern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Ahern more than expected).

Fields of papers citing papers by Elizabeth Ahern

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Ahern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Ahern. The network helps show where Elizabeth Ahern may publish in the future.

Co-authorship network of co-authors of Elizabeth Ahern

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Ahern. A scholar is included among the top collaborators of Elizabeth Ahern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Ahern. Elizabeth Ahern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Drummond, Katharine J., Anthony Dowling, Iwan Bennett, et al.. (2024). Improving Clinical Registry Data Quality via Linkage With Survival Data From State-Based Population Registries. JCO Clinical Cancer Informatics. 8(8). e2400025–e2400025. 1 indexed citations
2.
Rasco, Drew, Meredith McKean, Andrew Haydon, et al.. (2024). Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2527–2527. 1 indexed citations
3.
Gately, Lucy, Katharine J. Drummond, Anthony Dowling, et al.. (2024). Evolving Practice and Outcomes in Grade 2 Glioma: Real-World Data from a Multi-Institutional Registry. Cancers. 16(20). 3514–3514.
4.
Wyant, Timothy, Sophia Frentzas, Elizabeth Ahern, et al.. (2023). Abstract C033: Preliminary pharmacodynamic evaluation of AU-007 in phase 1 dose escalation trial in patients with advanced solid tumors. Molecular Cancer Therapeutics. 22(12_Supplement). C033–C033. 1 indexed citations
5.
6.
Ahern, Elizabeth, Teresa Brown, Brett Hughes, et al.. (2022). Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment. British Journal Of Nutrition. 129(3). 406–415. 15 indexed citations
7.
Gately, Lucy, Katharine J. Drummond, Mark Rosenthal, et al.. (2022). Beyond standard data collection – the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry). BMC Cancer. 22(1). 604–604. 4 indexed citations
8.
Ahern, Elizabeth, et al.. (2022). Scoping to analyze oncology trial participation in Australia. Seminars in Oncology. 49(2). 178–181. 1 indexed citations
9.
Parakh, Sagun, Daniel Roos, Amal Abou‐Hamden, et al.. (2022). Adult medulloblastoma in an Australian population. Journal of Clinical Neuroscience. 102. 65–70. 1 indexed citations
10.
11.
McCuaig, Robert, Michelle Melino, Daniel J. Rawle, et al.. (2021). Author Correction: Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication. Cell Discovery. 7(1). 58–58. 1 indexed citations
12.
Ahern, Elizabeth, Natasha Roberts, Bryan Chan, et al.. (2021). Semiqualitative research protocol to explore cancer care workforce perceptions of the health system response to COVID-19 preparations in Southeast Queensland, Australia. BMJ Open. 11(5). e044655–e044655. 2 indexed citations
13.
McCuaig, Robert, Michelle Melino, Daniel J. Rawle, et al.. (2021). Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication. Cell Discovery. 7(1). 37–37. 13 indexed citations
14.
Riddell, Andrew D., Cheng Liu, Vicki Whitehall, et al.. (2020). PET Imaging Quantifying 68Ga-PSMA-11 Uptake in Metastatic Colorectal Cancer. Journal of Nuclear Medicine. 61(11). 1576–1579. 21 indexed citations
15.
16.
Ahern, Elizabeth, et al.. (2019). Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib. BMJ Case Reports. 12(12). e232868–e232868. 7 indexed citations
17.
Ahern, Elizabeth, E Ballard, Michele W.L. Teng, et al.. (2019). Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN).. Journal of Clinical Oncology. 37(8_suppl). TPS129–TPS129.
18.
Harjunpää, Heidi, Stephen J. Blake, Elizabeth Ahern, et al.. (2018). Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. OncoImmunology. 7(7). e1445949–e1445949. 37 indexed citations
19.
Ahern, Elizabeth, Mark J. Smyth, William C. Dougall, & Michele W.L. Teng. (2018). Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy. Nature Reviews Clinical Oncology. 15(11). 676–693. 76 indexed citations
20.
Young, Arabella, Shin Foong Ngiow, Jason Madore, et al.. (2017). Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. Cancer Research. 77(17). 4684–4696. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gregory Pennock Breakdown of academic impact, for papers by Limei Yin Breakdown of academic impact, for papers by Taylor R. Cushman Breakdown of academic impact, for papers by Laura Mansi Breakdown of academic impact, for papers by Giulia Mazzaschi Breakdown of academic impact, for papers by Edit Porpaczy Breakdown of academic impact, for papers by Fiona Miall Breakdown of academic impact, for papers by Lucía Teijeira Breakdown of academic impact, for papers by Pia Herbolsheimer Breakdown of academic impact, for papers by Henriette Lindberg
Rankless by CCL
2026